Curcumin Maintenance Therapy for Ulcerative Colitis: Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial

Hanai, Hiroyuki; Iida, Takayuki; Takeuchi, Ken; Watanabe, Fumio; Maruyama, Yasuhiko; Andoh, Akira; Tsujikawa, Tomoyuki; Fujiyama, Y; Mitsuyama, Keiichi; Sata, Michio; Yamada, Masami; Iwaoka, Yasushi; Kanke, Kazunari; Hiraishi, Hideyuki; Hirayama, Kazuhisa; Arai, Hajime; Yoshii, Shigehito; Uchijima, Masato; Nagata, Toshi; Koide, Yukio

doi:10.1016/j.cgh.2006.08.008

Cited by 577 publications

(382 citation statements)

References 29 publications

Supporting

Mentioning

362

Contrasting

Unclassified

Order By: Relevance

“…In a subsequent randomized, double-blind, placebo-controlled multicenter trial [188], Hanai et al demonstrated curcumin's ability to safely and effectively prevent the relapse of quiescent ulcerative colitis when delivered as maintenance therapy. The 89 patients enrolled in the trial were randomly assigned to a 6-month regimen of either placebo (n = 44) or curcumin 1000 mg after breakfast and 1000 mg after dinner (n = 45) in combination with sulfasalazine or mesalamine.…”

Section: 13mentioning

confidence: 99%

Curcumin as “Curecumin”: From kitchen to clinic

Goel

Kunnumakkara

Aggarwal

2008

Biochemical Pharmacology

1,864

1,290

View full text Add to dashboard Cite

Section: 13mentioning

confidence: 99%

Curcumin as “Curecumin”: From kitchen to clinic

Goel

Kunnumakkara

Aggarwal

2008

Biochemical Pharmacology

1,864

1,290

View full text Add to dashboard Cite

“…All patients with proctitis improved, and four had their concomitant medications reduced; four of the five CD patients had lowered CDAI scores and sedimentation rates. Sixthly, in a randomized multicentre doubleblind, placebo-controlled trial, curcumin was examined as a maintenance therapy for UC and found to produce favourable effects (Hanai et al, 2006). Of 89 patients with UC, 45 received 1 g of curcumin after breakfast and 1 g after their evening meal, plus sulfasalazine and mesalamine for 6 months.…”

Section: Inflammatory Bowel Diseasementioning

confidence: 99%

Curcumin: an orally bioavailable blocker of TNF and other pro‐inflammatory biomarkers

Aggarwal

Gupta

Sung

2013

British J Pharmacology

322

239

View full text Add to dashboard Cite

TNFs are major mediators of inflammation and inflammation-related diseases, hence, the United States Food and Drug Administration (FDA) has approved the use of blockers of the cytokine, TNF-a, for the treatment of osteoarthritis, inflammatory bowel disease, psoriasis and ankylosis. These drugs include the chimeric TNF antibody (infliximab), humanized TNF-a antibody (Humira) and soluble TNF receptor-II (Enbrel) and are associated with a total cumulative market value of more than $20 billion a year. As well as being expensive ($15 000-20 000 per person per year), these drugs have to be injected and have enough adverse effects to be given a black label warning by the FDA. In the current report, we describe an alternative, curcumin (diferuloylmethane), a component of turmeric (Curcuma longa) that is very inexpensive, orally bioavailable and highly safe in humans, yet can block TNF-a action and production in in vitro models, in animal models and in humans. In addition, we provide evidence for curcumin's activities against all of the diseases for which TNF blockers are currently being used. Mechanisms by which curcumin inhibits the production and the cell signalling pathways activated by this cytokine are also discussed. With health-care costs and safety being major issues today, this golden spice may help provide the solution. LINKED ARTICLESThis article is part of a themed section on Emerging Therapeutic Aspects in Oncology. To view the other articles in this section visit http://dx

show abstract

“…Dhillon et al (33) studied the efficacy of curcumin on patients with advanced pancreatic cancer, and demonstrated that oral curcumin administration exerted biological activity in some patients. Hanai et al (34) conducted a double-blind, placebo-controlled trial in 89 patients with ulcerative colitis (UC); curcumin was shown to reduce the incidence of UC and may be considered a promising treatment for UC. In addition, a blind pilot study demonstrated that abdominal pain and the discomfort score of patients with IBS were significantly reduced following treatment with curcumin (35).…”

mentioning

confidence: 99%

Curcumin upregulates Nrf2 nuclear translocation and protects rat hepatic stellate cells against oxidative stress

Liu

Dou

Zheng

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract. The present study aimed to investigate the protective role of curcumin against oxidative stress in rat hepatic stellate cells (HSCs)-T6, and to determine the possible underlying mechanisms. HSC-T6 cells were divided into three groups: Negative control group, oxidant-treated group and curcumin-treated group. Flow cytometry and spectrophotometry were used to measure the production of reactive oxygen species (ROS), and the levels of malondialdehyde (MDA) and glutathione (GSH). Immunocytochemistry and a radioimmunoassay were used to determine the expression of smooth muscle α-actin (α-SMA) and the secretion of extracellular matrix (ECM) molecules. In addition, western blotting and immunocytochemistry were used to determine the expression levels of nuclear factor-erythroid 2-related factor (Nrf2). Treatment with glucose oxidase (GO) significantly stimulated the formation of ROS and increased the production of MDA, as compared with the control cells; however, the production of GSH was only slightly increased. In addition, treatment with GO significantly promoted the expression of α-SMA and the secretion of ECM molecules. Conversely, treatment with curcumin significantly decreased the levels of ROS and MDA, and significantly increased the levels of GSH. Curcumin significantly inhibited the expression of α-SMA and decreased the secretion of ECM molecules. Furthermore, treatment with curcumin significantly increased the nuclear expression levels of Nrf2. These results indicated that curcumin may protect rat HSCs against oxidative stress and inhibit the GO-induced activation and secretion of ECM molecules in vitro. These effects were mediated by the upregulation of Nrf2 nuclear translocation. IntroductionPrevious studies have demonstrated that oxidative stress has a significant role in the occurrence and progression of hepatitis and hepatic fibrosis (1-4). Oxidative stress results from the excessive production of reactive oxygen species (ROS), and the inability of an organism to eliminate them. Excessive ROS lead to lipid peroxidation, protein and DNA damage, and injury to cellular structure and function (5). Numerous studies have reported the important role of ROS in various types of hepatic injury (6-10). In addition to ROS-induced inflammation, ROS may lead to loss of normal regulatory functions, resulting in tissue injury and excessive repair, and the development of hepatitis and hepatic fibrosis (11,12). It has previously been demonstrated that activation of hepatic stellate cells (HSCs) has a key role in the progression of hepatic fibrosis; therefore, HSCs are considered important target cells in hepatic fibrosis research (13). Furthermore, HSCs can be activated by oxidative stress and transformed into myofibroblasts. Myofibroblasts synthesize abundant extracellular matrix (ECM) molecules, which may lead to hepatic fibrosis (14); therefore, how to inhibit the activation of HSCs exposed to oxidative stress requires further investigation. Nuclear factor-erythroid 2-related factor (Nrf2) is a transcription fa...

show abstract

Curcumin Maintenance Therapy for Ulcerative Colitis: Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial

Cited by 577 publications

References 29 publications

Curcumin as “Curecumin”: From kitchen to clinic

Curcumin as “Curecumin”: From kitchen to clinic

Curcumin: an orally bioavailable blocker of TNF and other pro‐inflammatory biomarkers

Curcumin upregulates Nrf2 nuclear translocation and protects rat hepatic stellate cells against oxidative stress

Contact Info

Product

Resources

About